PMID- 28978165
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 40
DP  - 2017 Sep 15
TI  - Comparative efficacy and safety of bone-modifying agents for the treatment of 
      bone metastases in patients with advanced renal cell carcinoma: a systematic 
      review and meta-analysis.
PG  - 68890-68898
LID - 10.18632/oncotarget.20323 [doi]
AB  - OBJECTIVE: To determine the comparative efficacy and safety of all available 
      bone-modifying agents (BMAs) for the treatment of bone metastases in patients 
      with advanced renal cell carcinoma (RCC). RESULTS: Three studies (259 patients) 
      were identified for the systematic review. Two studies that compared zoledronic 
      acid with placebo or no zoledronic acid showed that zoledronic acid reduced the 
      risk of skeletal-related events (SREs) by 68% (pooled hazard ratio [HR]: 0.32; 
      95% confidence interval [CI]: 0.19-0.55). The quality of evidence was moderate. 
      The incidence of serious adverse events (AEs) was identical (80%) for both 
      treatment arms in one study and not reported in the other study. In the third 
      study that compared denosumab and zoledronic acid among patients with solid 
      tumors or myeloma, a post-hoc subgroup analysis with individual patient data (155 
      patients) showed an HR of 0.71 (95% CI: 0.43-1.17) for SREs and a risk ratio of 
      0.86 (95% CI: 0.68-1.08) for serious AEs for denosumab compared to zoledronic 
      acid. MATERIALS AND METHODS: We searched the MEDLINE database, Cochrane Library, 
      WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov 
      database up to January 2017 without language restriction. Only randomized 
      controlled trials were included. When relevant data were missing, we contacted 
      the investigators of the original study. The Grading of Recommendation 
      Assessment, Development, and Evaluation approach was used to assess the evidence 
      certainty. CONCLUSIONS: Our moderate-quality evidence indicates that zoledronic 
      acid significantly reduces SREs risk among patients with bone metastases of RCC.
FAU - Omae, Kenji
AU  - Omae K
AD  - Department of Healthcare Epidemiology, Kyoto University Graduate School of 
      Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, 
      Japan.
AD  - Center for Innovative Research for Communities and Clinical Excellence, Fukushima 
      Medical University, Fukushima 960-1295, Japan.
AD  - Department of Urology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
FAU - Tsujimoto, Yasushi
AU  - Tsujimoto Y
AD  - Department of Healthcare Epidemiology, Kyoto University Graduate School of 
      Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, 
      Japan.
FAU - Honda, Michitaka
AU  - Honda M
AD  - Department of Surgery, Southern TOHOKU Research Institute for Neuroscience, 
      Southern TOHOKU General Hospital, 7-115 Yatsuyamada, Koriyama, Fukushima 
      963-8052, Japan.
FAU - Kondo, Tsunenori
AU  - Kondo T
AD  - Department of Urology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
FAU - Tanabe, Kazunari
AU  - Tanabe K
AD  - Department of Urology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
FAU - Fukuhara, Shunichi
AU  - Fukuhara S
AD  - Department of Healthcare Epidemiology, Kyoto University Graduate School of 
      Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, 
      Japan.
AD  - Center for Innovative Research for Communities and Clinical Excellence, Fukushima 
      Medical University, Fukushima 960-1295, Japan.
FAU - Furukawa, Toshi A
AU  - Furukawa TA
AD  - Department of Health Promotion and Human Behavior, Kyoto University Graduate 
      School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto 
      606-8501, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170818
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5620305
OTO - NOTNLM
OT  - bisphosphonate
OT  - bone-modifying agent
OT  - denosumab
OT  - renal cell carcinoma
OT  - zoledronate
COIS- CONFLICTS OF INTEREST None declared.
EDAT- 2017/10/06 06:00
MHDA- 2017/10/06 06:01
PMCR- 2017/09/15
CRDT- 2017/10/06 06:00
PHST- 2017/06/30 00:00 [received]
PHST- 2017/08/06 00:00 [accepted]
PHST- 2017/10/06 06:00 [entrez]
PHST- 2017/10/06 06:00 [pubmed]
PHST- 2017/10/06 06:01 [medline]
PHST- 2017/09/15 00:00 [pmc-release]
AID - 20323 [pii]
AID - 10.18632/oncotarget.20323 [doi]
PST - epublish
SO  - Oncotarget. 2017 Aug 18;8(40):68890-68898. doi: 10.18632/oncotarget.20323. 
      eCollection 2017 Sep 15.